Racura Oncology has received approval to escalate the dosage of its drug RC220 in the HARNESS-1 trial, aimed at treating EGFR-mutant lung cancer, marking a significant step in cancer research.

Watch the presentations from three ASX-listed biotechs at the forefront of promising new cancer therapies, each advancing treatments for diseases with significant unmet medical need. Inquiries: info@monsoon.com.au The session includes company updates, pipeline progress and outlook discussions from: ✅ 03:00 Racura Oncology (ASX: RAC) Racura is a Phase 3 clinical-stage company advancing RC220 across three active oncology programs. RC220 has been discovered to silence MYC — a target implicated in 70% of all cancers and long considered undruggable — via DNA G4 binding. Active programs include a Phase 3 AML trial, the HARNESS-1 Phase 1 trial in EGFR-mutant NSCLC combining RC220 with Tagrisso®, and the CPACS-1 cardioprotection trial with patients already dosed in Hong Kong and Australia. First patient dosed in both Phase 3 AML and HARNESS-1 are targeted in 2026, with HARNESS-1 carrying explicit potential for FDA Accelerated Approval. Website: https://www.racuraoncology.com/ ✅ 25:44 Amplia Therapeutics (ASX: ATX | OTCQB: INNMF) Amplia is a clinical-stage Australian biotech developing best-in-class FAK inhibitors for fibrotic cancers. Its lead drug narmafotinib has delivered 5 confirmed complete responses in advanced pancreatic cancer — a 7.8% complete response rate confirmed by independent central review, compared to 0.2% for chemotherapy alone, and never before seen in this indication. The ACCENT trial achieved a 36% objective response rate and median overall survival of 11.1 months. A registration-enabling Phase 2b study is now underway, designed in alignment with FDA feedback, with a new ovarian cancer trial (PRROSE) and kRAS inhibitor partnering discussions further expanding the pipeline. Website: https://www.ampliatx.com ✅ 47:45 Prescient Therapeutics (ASX: PTX) Prescient is developing the world's only GGTase-1 inhibitor in clinical development — a first-in-class targeted therapy advancing through Phase 2a in Cutaneous T-Cell Lymphoma (CTCL), a blood cancer with no satisfactory treatment options. Phase 1b results in CTCL delivered a 43% response rate, 100% clinical benefit rate, 12.4-month duration of response, and zero serious treatment-related adverse events. The Phase 2a trial has enrolled 18 patients across 12 active sites in Australia, the US and Italy, scaling toward 16 sites globally. GGTase-1 biology is implicated in approximately 22% of all cancers, with the CTCL market forecast at ~US$1.2bn annually by 2034. Website: https://www.ptxtherapeutics.com

Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing a combination of RC220 and osimertinib for EGFR-mutant NSCLC. The post First patient dosed in Racura’s HARNESS-1 trial of RC220 appeared first on Clinical Trials Arena .

Racura Oncology has dosed the first patient in the Phase Ia/b HARNESS-1 trial assessing a combination of RC220 and osimertinib for EGFR-mutant NSCLC.

Racura Oncology starts Harness-1 Phase 1 with first patient dosed for RC220 + osimertinib in EGFR-mutant NSCLC; early safety data awaited.

Racura Oncology has begun the HARNESS-1 Phase 1 clinical trial, examining RC220 combined with osimertinib in EGFR-mutant non-small cell lung cancer.

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung cancer. The study will assess safety, pharmacokinetics, ctDNA dynamics and early clinical activity of RC220 as a strategy to address...

Racura Oncology's ongoing CPACS clinical trial for RC220 has received a positive recommendation from its Safety Review Committee, paving the way for further development.

Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.

Racura Oncology (ASX:RAC) final patient in first cohort dosed with RC220 in cardioprotection and anticancer synergy.

Racura Oncology shares (ASX:RAC) jumped more than 20% today after the company announced the first patient dosing at its Hong Kong clinical site, marking a critical operational milestone for its multi-...

Racura Oncology (ASX:RAC) receives governance approval to launch its HARNESS-1 clinical trial assessing the safety and tolerability of R22.

Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.

Race Oncology (ASX:RAC) has identified major new opportunities in two new cancer indications for its RC220 therapy.

Race Oncology extends patent protection and advances Phase 1 RC220 trial in September quarter  Proactive financial news

Race Oncology’s (ASX:RAC) achieves breakthrough with its lead candidate RC220 uncovering primary mechanism of action of bisantrene (RCDS1).

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) is an asset listed on the ASX, and part of the Health Care sector. Grafa’s asset page shows Race Oncology’s share price, chart, trading

Race Oncology (ASX:RAC) announced the activation of a second clinical trial site at the Central Coast Local Health District (Gosford and Wyong Hospitals) for